Capricor Therapeutics, Inc. (CAPR)
26.01
-0.15
(-0.57%)
USD |
NASDAQ |
Jun 09, 16:00
26.04
+0.03
(+0.12%)
After-Hours: 20:00
Capricor Therapeutics Research and Development Expense (Quarterly) : 27.10M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| REGENXBIO, Inc. | 53.48M |
| Inovio Pharmaceuticals, Inc. | 13.75M |
| Regeneron Pharmaceuticals, Inc. | 1.420B |
| iBio, Inc. | 3.254M |
| AbbVie, Inc. | 2.472B |